Bagsværd, Denmark, 3 December 2018 - On 5 November 2018, Novo Nordisk initiated a share repurchase programme in accordance with Article 5 of Regulation No. 596/2014 of the European...
Investing.com – Denmark stocks were higher after the close on Friday, as gains in the Software & Computer Services, Technology and Oil & Gas sectors led shares higher. At the...
Investing.com – Denmark stocks were higher after the close on Friday, as gains in the Healthcare, Personal & Household Goods and Consumer Goods sectors led shares higher. At the...
A month has gone by since the last earnings report for Model N (MODN). Shares have added about 2.4% in that time frame, outperforming the S&P 500.Will the recent positive trend...
Shares of clinical-stage biopharmaceutical company Zafgen, Inc. (NASDAQ:ZFGN) slumped 40.5% after the company announced that the FDA has placed a clinical hold on the...
Futures waver as European shares hold onto positive territory amid heightened trade tensions APEC summit ends without joint statement for the first time ever after US attack on...
|Type||5 mins||15 mins||Hourly||Daily||Monthly|
|Moving Averages||Strong Sell||Strong Sell||Strong Sell||Strong Sell||Sell|
|Technical Indicators||Strong Sell||Strong Sell||Strong Sell||Strong Sell||Sell|
|Summary||Strong Sell||Strong Sell||Strong Sell||Strong Sell||Sell|
Filter Table By:
|Pattern||Timeframe||Reliability||Candles Ago||Candle Time|
|Bullish doji Star||1H||Current|
|Downside Gap Three Methods||1M||1||Nov 18|
|Engulfing Bearish||1W||1||Dec 02, 2018|
|Falling Three Methods||1H||1||Dec 11, 2018 10:00AM|
|Bank of America||24.58||25.40||24.53||-0.18||-0.73%||78.55M||11/12|
Novo Nordisk A/S is a global healthcare company engaged in diabetes care. The Company is also engaged in the discovery, development, manufacturing and marketing of pharmaceutical products. The Company operates through two business segments: diabetes and obesity care, and biopharmaceuticals. The Company's diabetes and obesity care segment covers insulin, GLP-1, other protein-related products, such as glucagon, protein-related delivery systems and needles, and oral anti-diabetic drugs. The Company's biopharmaceuticals segment covers the therapy areas of hemophilia care, growth hormone therapy and hormone replacement therapy. The Company also offers Saxenda product to treat obesity. It offers a range of products, including NovoLog/NovoRapid; NovoLog Mix/NovoMix; Prandin/NovoNorm; NovoSeven; Norditropin, and Vagifem. As of December 31, 2016, it marketed its products in over 180 countries. Its regional structure consists of two commercial units: North America and International Operations.Read More
|U.S. Commodity Futures Trading Commission (United States), Securities and Exchange Commission (United States)||$0||Start Trading|
|National Futures Association (United States), Financial Industry Regulatory Authority (United States), Securities Investor Protection Corporation (United States)||$2000||Start Trading|
|U.S. Commodity Futures Trading Commission (United States)||Start Trading|
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.